News | May 10, 2021
Cipla signs agreement with Lilly to expand access to COVID-19 treatment in India
Baricitinib was issued a restricted emergency use approval by the Central Drugs Standard Control Organization (CDSCO)
Baricitinib was issued a restricted emergency use approval by the Central Drugs Standard Control Organization (CDSCO)
Molnupiravir is an investigational oral antiviral drug currently being studied in a Phase 3 trial for the treatment of non-hospitalized patients with confirmed COVID-19
The company has reported total income of Rs.14759 crores during the 9 months period ended December 31, 2020.
She has held senior positions at Coca-Cola in China and PepsiCo in India
Anushree has been with Abbott since 2021 and currently serving as Head of Strategy and Portfolio
Before joining Sun Pharma, Tulla served as Senior Vice President and Chief Commercial Head – Acute Cluster at Cipla
Prior to joining Neuland, Deshmukh held several key positions at Cipla
Prithwish has close to 28 years of experience in a Commercial role
The company's portfolio includes 21 commercialized products, 19 approved ANDAs, 4 CGT designations, 6 filed ANDAs, and 45 products in its pipeline
The product will be marketed by Dr. Reddy's
Subscribe To Our Newsletter & Stay Updated
